CSIMarket Company Name, Ticker, Industry, else..
 
Biofrontera Inc   (NASDAQ: BFRI)
 

Biofrontera Inc's Suppliers Performance

BFRI's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
BFRI Costs vs Sales of Suppliers Growth Biofrontera Inc's cost of sales deteriorated by -94.33 % year on year, relative to one quarter ago cost of sales fell by -92.63 % in Q2.

• More on BFRI Suppliers



Biofrontera Inc's cost of sales deteriorated by -94.33 % year on year, compare to one quarter ago cost of sales fell by -92.63 % in Q2.

• More on BFRI Suppliers




Biofrontera Inc's Comment on Supply Chain


The company previously relied on Biofrontera Pharma as the primary supplier and manufacturer of its products. Following a Strategic Transaction, the company assumed full control of the Ameluz New Drug Application and Investigational New Drug, enabling it to take full responsibility for manufacturing Ameluz and RhodoLED Lamps in the United States. Temporarily, the company will continue to depend on Biofrontera Pharma for Ameluz manufacturing until all required licenses and contracts are finalized. The company has entered into an agreement with Midas Pharma GmbH in Germany for the primary procurement of the active pharmaceutical ingredient (API) and has identified a secondary API source with plans to establish a similar agreement. Ameluz production is conducted by contract manufacturers Glaropharm AG in Switzerland and Pharbil Waltrop GmbH in Germany, with Pharbil Waltrop GmbH recently qualified to support supply chain stability and manage tariff impacts. RhodoLED Lamp production is currently performed by Biofrontera Pharma in Leverkusen, Germany, with responsibility set to transfer to the company pursuant to the Strategic Transaction.

Biofrontera Inc's Comment on Supply Chain


The company previously relied on Biofrontera Pharma as the primary supplier and manufacturer of its products. Following a Strategic Transaction, the company assumed full control of the Ameluz New Drug Application and Investigational New Drug, enabling it to take full responsibility for manufacturing Ameluz and RhodoLED Lamps in the United States. Temporarily, the company will continue to depend on Biofrontera Pharma for Ameluz manufacturing until all required licenses and contracts are finalized. The company has entered into an agreement with Midas Pharma GmbH in Germany for the primary procurement of the active pharmaceutical ingredient (API) and has identified a secondary API source with plans to establish a similar agreement. Ameluz production is conducted by contract manufacturers Glaropharm AG in Switzerland and Pharbil Waltrop GmbH in Germany, with Pharbil Waltrop GmbH recently qualified to support supply chain stability and manage tariff impacts. RhodoLED Lamp production is currently performed by Biofrontera Pharma in Leverkusen, Germany, with responsibility set to transfer to the company pursuant to the Strategic Transaction.







BFRI's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Biofrontera Inc 14.86 45.96 -6.37 92
SUBTOTAL 0.00 0.00 0.00 -


Sources: Biofrontera Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Biofrontera Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.